Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,978,216
  • Shares Outstanding, K 2,504,138
  • Annual Sales, $ 42,147 M
  • Annual Income, $ 3,256 M
  • 60-Month Beta 0.60
  • Price/Sales 3.05
  • Price/Cash Flow 7.33
  • Price/Book 1.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.75
  • Number of Estimates 2
  • High Estimate 0.82
  • Low Estimate 0.67
  • Prior Year 0.74
  • Growth Rate Est. (year over year) +1.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.11 +11.34%
on 05/01/20
50.23 -2.23%
on 05/06/20
+0.11 (+0.22%)
since 04/29/20
3-Month
37.62 +30.54%
on 03/23/20
51.29 -4.25%
on 04/27/20
+2.86 (+6.18%)
since 02/28/20
52-Week
37.62 +30.54%
on 03/23/20
51.84 -5.27%
on 01/10/20
+8.29 (+20.31%)
since 05/29/19

Most Recent Stories

More News
Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant

Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.

SNY : 49.11 (+0.88%)
MRNA : 61.50 (+10.73%)
GSK : 41.92 (+0.91%)
VIR : 34.18 (+8.30%)
Protalix Submits BLA for Fabry Disease Candidate PRX-102

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

SNY : 49.11 (+0.88%)
PLX : 3.34 (-5.92%)
AGEN : 3.73 (+29.51%)
TAK : 19.50 (+1.46%)
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN

Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.

SNY : 49.11 (+0.88%)
AZN : 54.60 (+2.06%)
RHHBY : 43.3500 (-1.37%)
MRK : 80.72 (+2.13%)
LLY : 152.95 (+1.53%)
GSK : 41.92 (+0.91%)
BMY : 59.72 (-0.15%)
Sanofi's Dupixent Gets FDA Approval for Eczema in Children

Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.

REGN : 612.81 (+5.98%)
SNY : 49.11 (+0.88%)
LLY : 152.95 (+1.53%)
ABBV : 92.67 (+2.93%)
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.

JNJ : 148.75 (+1.21%)
SNY : 49.11 (+0.88%)
PFE : 38.19 (+0.03%)
MRK : 80.72 (+2.13%)
MRNA : 61.50 (+10.73%)
GSK : 41.92 (+0.91%)
NVAX : 46.04 (+2.68%)
IBB : 134.74 (+1.82%)
XBI : 103.56 (+0.99%)
BBH : 160.91 (+2.60%)
BBC : 41.15 (+0.59%)
ARKG : 46.34 (+2.32%)
BNTX : 49.53 (+5.68%)
GNOM : 16.51 (+0.84%)
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

REGN : 612.81 (+5.98%)
SNY : 49.11 (+0.88%)
NVAX : 46.04 (+2.68%)
INO : 14.75 (+10.49%)
ICPT : 72.26 (-0.66%)
ARGX : 219.30 (+3.60%)
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA

Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.

REGN : 612.81 (+5.98%)
SNY : 49.11 (+0.88%)
ALNY : 135.27 (+1.63%)
NVS : 87.43 (+1.33%)
Merck Inks 3 Deals for Coronavirus Anti-infective & Vaccines

Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19....

JNJ : 148.75 (+1.21%)
SNY : 49.11 (+0.88%)
PFE : 38.19 (+0.03%)
MRK : 80.72 (+2.13%)
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline

SNY : 49.11 (+0.88%)
PFE : 38.19 (+0.03%)
MRNA : 61.50 (+10.73%)
GSK : 41.92 (+0.91%)
BNTX : 49.53 (+5.68%)
Regeneron (REGN) to Buy Back Part of Its Stake Held by Sanofi

Regeneron (REGN) commences underwritten public secondary offering of its common stock held by Sanofi and repurchases shares for $5 billion.

REGN : 612.81 (+5.98%)
SNY : 49.11 (+0.88%)
GILD : 77.83 (+3.33%)
BAYRY : 17.0999 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 50.18
1st Resistance Point 49.64
Last Price 49.11
1st Support Level 48.41
2nd Support Level 47.72

See More

52-Week High 51.84
Last Price 49.11
Fibonacci 61.8% 46.41
Fibonacci 50% 44.73
Fibonacci 38.2% 43.05
52-Week Low 37.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar